Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Rhea-AI Summary

Tactile Medical (Nasdaq: TCMD) entered an exclusive U.S. distribution agreement with ElastiMed to supply the MyoSleeve™ wearable, non-pneumatic lower-leg compression device to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients. The device has FDA 510(k) clearance for chronic edema, lymphedema, and venous insufficiency.

According to Tactile Medical, it paid $3 million upfront for exclusive VA/DoD distribution rights and agreed to minimum purchase and promotional obligations. The company plans to use its existing sales, billing, and patient-support infrastructure to commercialize MyoSleeve as an early-stage and complementary therapy option.

Positive

• Exclusive VA/DoD distribution rights for MyoSleeve in the U.S.
• $3 million upfront secures access to defined VA and DoD patient populations
• Portfolio expansion into earlier-stage chronic swelling and complementary therapy segment
• Leverages existing sales, billing, and patient-support infrastructure for commercialization
• MyoSleeve holds FDA 510(k) clearance for multiple chronic swelling indications

Negative

• $3 million upfront payment represents immediate cash outlay
• Agreement includes minimum purchase obligations, creating fixed future commitments

News Explained

Tactile has committed $3 million plus minimum purchases for exclusive VA/DoD rights, with no disclosed share issuance.

On July 13, 2026, Tactile Medical entered an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve in VA and DoD systems. The agreement gives Tactile exclusive distribution rights, records a $3 million upfront payment to ElastiMed, and commits Tactile to minimum purchases plus marketing and sales promotion.

The stated lifecycle state is an entered agreement: the upfront payment has been made, while minimum purchases and promotion remain committed obligations. The release describes rights to distribute the device within the VA and DoD systems; it does not disclose an issuance of shares or a change in existing ownership. Under the supplied dilution definition, issuing additional shares would reduce an existing holder’s percentage ownership absent offsets; no such issuance is disclosed here.

The first-quarter report showed $74,993,000 in cash and equivalents at March 31, 2026, while the release reports the separate $3 million upfront payment. Subsequent quarterly filings are the relevant place to track the agreement’s minimum-purchase obligations, marketing and sales costs, and any revenue from MyoSleeve.

News Market Reaction – TCMD

-2.65%

5 alerts

-2.65% Session close to close

$672.85M Market Cap

0.9x Rel. Volume

In the Jul 13 session, TCMD declined 2.65%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The key development is TCMD’s exclusive VA and DoD distribution rights for MyoSleeve, secured with a...

Analysis

The key development is TCMD’s exclusive VA and DoD distribution rights for MyoSleeve, secured with a $3 million upfront payment. Investors may track how quickly prescriptions ramp and how this complements existing pneumatic compression devices within its chronic swelling portfolio.

Key Figures

Upfront payment: $3 million

1 metrics

Upfront payment $3 million Exclusive VA/DoD U.S. distribution rights for MyoSleeve

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Product launch	Positive	+1.8%	Full commercial launch of next-generation AffloVest airway clearance therapy system.
May 20	Conference presentation	Neutral	+3.2%	Announcement of management presentation at William Blair Growth Stock Conference.
May 04	Earnings report	Positive	+7.2%	Q1 2026 results with strong revenue growth and updated full-year guidance.
Apr 20	Earnings date	Neutral	-2.8%	Notice of upcoming release and call for Q1 2026 financial results.
Mar 09	Board appointment	Positive	+0.5%	Addition of Andrea Pearson to board and key governance committees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

TCMD has tended to trade higher on substantive product and earnings updates, while scheduling and administrative items have produced weaker or negative moves.

Key Terms

510(k) clearance, pneumatic compression device, electroactive polymer technology, venous insufficiency, +1 more

5 terms

510(k) clearance regulatory

"MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

pneumatic compression device medical

"complementary treatment to a traditional pneumatic compression device"

A pneumatic compression device is a medical device that uses inflatable sleeves or cuffs and timed air pressure cycles to squeeze limbs and promote blood flow, like a mechanical massage that helps prevent blood clots and reduces swelling. Investors care because these devices are sold to hospitals, clinics and patients, and their commercial value depends on clinical effectiveness, regulatory approvals, reimbursement rules and adoption by healthcare providers, all of which affect sales and revenue.

electroactive polymer technology technical

"MyoSleeve uses electroactive polymer technology to deliver dynamic compression"

A class of synthetic plastics that change shape, size, conductivity or other properties when exposed to an electrical signal, functioning like a soft, artificial muscle or switch. They are used to make sensors, tiny actuators, flexible electrodes and energy-harvesting or storage components, especially where lightweight, bendable materials are needed. Investors track them because they enable new products, manufacturing and regulatory paths, intellectual property and potential markets in medical devices, robotics and flexible electronics.

venous insufficiency medical

"indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency"

A vascular condition in which leg veins cannot efficiently return blood to the heart because valves and vein walls are weakened or damaged, causing blood to pool, swelling, skin changes, and sometimes ulcers. It matters to investors because the condition drives demand for medical devices, drugs, diagnostics, procedures, and long-term care resources; clinical trial results, regulatory approvals, reimbursement policies, and prevalence trends can all affect companies and markets like a building’s clogged plumbing driving need for repair products and services.

lymphedema medical

"treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency"

Lymphedema is a chronic swelling that happens when the body’s fluid-draining network can’t move fluid away from tissues, causing persistent puffiness, heaviness and sometimes skin changes. Investors pay attention because it represents a steady demand for diagnostics, drugs, devices and long-term care—think of it like a clogged drain that creates ongoing repair and maintenance needs, so new treatments or devices can shift patient outcomes and company revenue for years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression

MINNEAPOLIS, July 13, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced it has entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients across the United States. MyoSleeve expands Tactile Medical’s established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic swelling who may not yet require more intensive compression therapy. MyoSleeve may also be appropriate as a complementary treatment to a traditional pneumatic compression device and for patients who struggle with conservative therapy, or those with mobility-limiting cases.

Wrapped around the calf with the ability to be worn beneath clothing, MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract in sequence. The battery-powered device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller, and quietly delivers intermittent therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

Under the agreement, Tactile Medical holds exclusive U.S. distribution rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, the Company made an upfront payment of $3 million to ElastiMed. The Company also committed to certain minimum purchase obligations and marketing and sales promotion as it supports ElastiMed’s growth. The Company expects to leverage its established sales organization, billing and payment expertise, and patient support infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available by prescription, and appropriate patient selection is determined by the treating clinician.

“Our agreement with ElastiMed adds a differentiated, wearable compression option to Tactile Medical’s portfolio and reflects our strategy of expanding access to patient-focused solutions across the continuum of chronic swelling care,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “For the right patient, MyoSleeve offers unobtrusive compression therapy that fits into daily life, giving patients the freedom to stay mobile while engaged in their own care.”

“Partnering with Tactile Medical gives MyoSleeve a direct path to certain patients with chronic swelling who want to stay active while getting the treatment they need,” said Omer Zelka, Chief Executive Officer of ElastiMed. “It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading medical device partner.”

“Compression therapy is not one-size-fits-all. Clinicians achieve the best outcomes when they have a range of options that can be matched to disease severity, anatomy, and lifestyle,” said Tony Gasparis, MD, Chief Medical Officer of Tactile Medical. “MyoSleeve introduces an important new option for appropriately selected patients with lower-leg swelling, offering active compression that is well-suited for earlier stages of disease, where consistent therapy adherence is key to slowing disease progression. Importantly, MyoSleeve is designed to complement — not replace — advanced pneumatic compression therapies, which remain the standard of care for patients with more extensive or advanced disease.”

For more information about MyoSleeve, please visit https://tactilemedical.com/myosleeve/.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

About ElastiMed, Inc.

ElastiMed is a commercial-stage medical device company developing wearable therapeutic devices based on electroactive polymer (EAP) technology, designed to deliver dynamic compression in a comfortable, low-profile, and easy-to-use form.

Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com

FAQ

What did Tactile Medical (TCMD) announce about the MyoSleeve distribution deal on July 13, 2026?

Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device in VA and DoD systems. According to Tactile Medical, the deal targets lower-leg chronic swelling patients through its established commercial infrastructure.

How much did Tactile Medical (TCMD) pay ElastiMed in the MyoSleeve agreement?

Tactile Medical paid ElastiMed an upfront $3 million in connection with exclusive VA and DoD distribution rights for MyoSleeve. According to Tactile Medical, the agreement also includes minimum purchase obligations and marketing and sales promotion commitments to support ElastiMed’s growth.

What is MyoSleeve and which conditions can it treat for TCMD’s VA and DoD patients?

MyoSleeve is a discreet, battery-powered, wearable non-pneumatic compression device for the lower leg. According to Tactile Medical, it has FDA 510(k) clearance and is indicated for chronic swelling, including chronic edema, lymphedema, and venous insufficiency in appropriately selected patients.

How does the MyoSleeve device work in Tactile Medical’s chronic swelling portfolio?

MyoSleeve uses electroactive polymer technology and flexible bands that contract in sequence to deliver dynamic compression. According to Tactile Medical, it is an all-in-one, cable-free, intermittent therapy designed for daily wear and can complement traditional pneumatic compression devices.

What patient segment is Tactile Medical (TCMD) targeting with MyoSleeve in VA and DoD systems?

Tactile Medical is targeting appropriately selected patients in earlier stages of chronic swelling and those struggling with conservative therapy. According to Tactile Medical, MyoSleeve may also serve as a complementary treatment for patients who already use advanced pneumatic compression devices.

Does Tactile Medical’s MyoSleeve deal change the standard of care for lymphedema and venous disease?

According to Tactile Medical, MyoSleeve is designed to complement, not replace, advanced pneumatic compression therapies, which remain the standard of care for more extensive or advanced disease. The device adds a new option for earlier-stage and mobility-focused chronic swelling patients.

How will Tactile Medical (TCMD) commercialize MyoSleeve within VA and DoD networks?

Tactile Medical plans to leverage its established sales organization, billing and payment capabilities, and patient-support infrastructure. According to Tactile Medical, these resources will drive MyoSleeve commercialization, support market access initiatives, and fulfill the agreement’s marketing and minimum purchase obligations.